Trial Profile
A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching From Fixed Dose Abacavir (ABC)/Lamivudine [lamivudine/abacavir] (3TC) [Epzicom] to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) [emtricitabine/tenofovir disoproxil fumarate] [Truvada] in Virologically Suppressed, HIV 1 Infected Patients Maintained on a Ritonavir Boosted Protease Inhibitor Containing Antiretroviral Regimen.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; HIV protease inhibitors; Lamivudine/abacavir; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms SWIFT
- Sponsors Gilead Sciences
- 23 Oct 2011 Results presented at the 49th Annual Meeting of the Infectious Diseases Society of America.
- 12 Oct 2011 Results presented at the 13th European AIDS Conference.
- 20 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.